Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its ongoing radioligand therapy manufacturing expansion.
MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational antibody-drug conjugate (ADC) targeting B7H3 in various solid tumour types.
Samsung Biologics has entered into a definitive agreement, through its subsidiary Samsung Biologics America, to acquire Human Genome Sciences from GSK as part of its plan to expand manufacturing capabilities in the US.
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
The European Commission (EC) has approved Incyte’s Minjuvi (tafasitamab) in conjunction with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) who have received a minimum of one systemic therapy line.
Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics.
Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies for several targets in metabolic diseases.
Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.
Made Scientific and Cellergy Therapeutics have formed a manufacturing partnership to advance the latter’s CLG-001 mitochondrial therapy toward first-in-human studies.
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they supplied adulterated attention-deficit hyperactivity disorder (ADHD) medication to children in the US state.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.